<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785197</url>
  </required_header>
  <id_info>
    <org_study_id>FASTA</org_study_id>
    <nct_id>NCT03785197</nct_id>
  </id_info>
  <brief_title>Effects of a Clinical Dietary Intervention During Inpatient Treatment</brief_title>
  <acronym>FASTA</acronym>
  <official_title>Effects of a Clinical Dietary Intervention During Inpatient Treatment (Modified Fasting in Metabolic Syndrome, Osteoarthritis of the Hip or Knee, Rheumatoid Arthritis and Fibromyalgia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is a scientific and prospective documentation of the clinical
      effects of an inpatient treatment at the Immanuel Hospital of Berlin, in the department for
      complementary and integrative medicine, with the use of a modified fasting regime. A pre- and
      post- as well as group comparisons are planned. Patients that are admitted to the inpatient
      department for metabolic syndrome, osteoarthritis of the hip or knee, rheumatoid arthritis
      and fibromyalgia will be enrolled in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the beginning, during and at the end of the treatment at the inpatient department routine
      blood parameters, anthropometric parameters and certain scores and parameters specific to the
      different conditions will be measured. Questionnaires will be filled out by patients before
      and after the treatment as well as 3, 6 and 12 months after leaving the inpatient department.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibromyalgia Impact Questionnaire (FIQ)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; The FIQ is scored in such a way that a higher score indicates a greater impact of the syndrome on the person. Each of the 10 items has a maximum possible score of 10. Thus the maximum possible score is 100. The average FM patient scores about 50, severely afflicted patients are usually 70 plus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity Score 28 (DAS 28)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire with Clinical Examination; Change from Baseline in the DAS-28, range from 2.0 to 10.0 while higher values meaning a higher disease activity and below of 2.6 meaning remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; Change from Baseline in the HAQ, range from 0 to 3 while higher values meaning a higher grade of disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire consisting of 24 items divided into 3 subscales: Pain (5items), Stiffness (2 items), Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).
The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher values meaning a higher grade of disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Diabetes Self Care Activities Measure (SDSCA)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; 11 items with each item scored on a scale of 0-7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain on Visual Analogue Scale (VAS)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; HADS: Assessing full scale, range 0-42, lower score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale (PSS)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; Change from Baseline in the PSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 &amp; 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (WHO-5)</measure>
    <time_frame>Change Baseline, 2 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Questionnaire; Change from Baseline in the WHO-5, range from 0 to 100 % while higher values meaning a higher grade of well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-Mass-Index (BMI)</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Anthropometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Measuring systolic and diastolic blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h-Blood pressure</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Measuring systolic and diastolic blood pressure with Device &quot;Mobil-O-Graph&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood count</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>triglycerides (mmol/L), total cholesterol (mmol/L), LDL (mmol/L), HDL (mmol/L), fasting glucose (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>CRP in milligram per liter (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes (GOT, GPT)</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>Hepatic transaminases (GPT, GOT in U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stepcounter</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Everion&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Faros 180&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Everion&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Oxygenation</measure>
    <time_frame>Change Baseline, 2 weeks</time_frame>
    <description>With Device &quot;Everion&quot;</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Fibromyalgia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged modified fasting</intervention_name>
    <description>The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, serum, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Regular hospitalised patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is consents to participating in the trial during the first 24h of his or
             her stay in the inpatient naturopathic department of the Immanuel Hospital.

          -  Written informed consent is given

          -  The referral diagnosis is one of the following: diabetes mellitus type 2/metabolic
             syndrome, osteoarthritis of the hip, osteoarthritis of the knee, rheumatoid arthritis,
             fibromyalgia.

        Exclusion Criteria:

          -  Language barries to understanding the instructions of the study personnel

          -  Dementia or other strong cognitive impairment

          -  Pregnant or lactating women

          -  Taking part in another study at the same time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Michalsen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Liebscher, Dr.</last_name>
    <phone>03080505770</phone>
    <email>daniela.liebscher@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Kessler, Dr.</last_name>
    <phone>03080505691</phone>
    <email>christian.kessler@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immanuel Hospital</name>
      <address>
        <city>Berlin-Wannsee</city>
        <state>Berlin</state>
        <zip>14109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Liebscher, Dr.</last_name>
      <phone>03080505770</phone>
      <email>daniela.liebscher@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Kessler, Dr.</last_name>
      <phone>03080505691</phone>
      <email>christian.kessler@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Michalsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fasting</keyword>
  <keyword>natural therapies</keyword>
  <keyword>prolonged fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

